COOPERATIVE-PFA:三种镇静方案用于房颤脉冲场消融的随机对照试验
主要终点为需干预或导致手术终止的低氧、低血压或高血压复合事件,瑞马唑仑-氯胺酮组发生率最低(27.9%),显著优于丙泊酚-阿片类间断推注组(85.7%)和全静脉麻醉组(66.7%),P<0.001。
要点
- 瑞马唑仑-氯胺酮深度镇静主要终点事件发生率27.9%,显著低于丙泊酚-阿片类间断推注(85.7%)和全静脉麻醉(66.7%)。
- 丙泊酚-阿片类间断推注组主要终点事件全部由低氧血症驱动,全静脉麻醉组全部由低血压驱动。
- 三组在平均手术时间、严重不良事件发生率和患者满意度评估方面均无差异。
核心结论
- 在房颤脉冲场消融中,瑞马唑仑-氯胺酮深度镇静优于丙泊酚-阿片类方案(间断推注或持续给药),低氧血症和低血压事件风险最低。
- 超过80%接受常规丙泊酚-阿片类深度镇静的患者发生低氧血症。
研究设计与样本
- 三臂随机对照试验,按1:1:1比例随机分配。
- 分组为:丙泊酚-阿片类间断推注深度镇静组(n=42)、瑞马唑仑-氯胺酮持续深度镇静组(n=43)、丙泊酚-阿片类全静脉麻醉组(n=42)。
- 使用FARAPULSE系统(Boston Scientific,MA)进行导管消融。
- 主要排除标准为阻塞性睡眠呼吸暂停综合征。
主要发现
- 主要终点发生率:丙泊酚-阿片类间断推注组85.7%,瑞马唑仑-氯胺酮组27.9%,全静脉麻醉组66.7%(P<0.001)。
- 丙泊酚-阿片类间断推注组主要终点事件100%由低氧血症驱动;全静脉麻醉组100%由低血压驱动。
- 瑞马唑仑-氯胺酮组低氧血症事件占50%,低血压事件占66.7%。
- 三组在平均手术时间、严重不良事件发生率和患者满意度评估方面无差异。
临床怎么用
- 房颤脉冲场消融时,可优先考虑瑞马唑仑-氯胺酮持续深度镇静以降低低氧血症和低血压事件风险。
- 使用常规丙泊酚-阿片类深度镇静时需警惕低氧血症,超过80%患者可能发生。
- 全静脉麻醉with secured airway需关注低血压事件。
局限性
- 主要排除标准为阻塞性睡眠呼吸暂停综合征,结果外推至该人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep analgosedation (DAS) or general anesthesia is mandatory for pulsed-field ablation of atrial fibrillation. In contrast to DAS, general anesthesia (conventional or total intravenous anesthesia [TIVA]) requires airway management. To find the optimal sedation regimen, this study compared ketamine-remimazolam DAS and propofol-opioid TIVA with propofol-opioid DAS, focusing on sedation-related adverse events. METHODS: Patients indicated for atrial fibrillation catheter ablation were randomly assigned at a 1:1:1 ratio to: (1) DAS using intermittent propofol-opioid boluses (arm P), (2) continuous remimazolam-ketamine DAS (arm R), or (3) continuous propofol-opioid TIVA with secured airway (arm TIVA). Catheter ablation was performed using the FARAPULSE system (Boston Scientific, MA). The major exclusion criterion was obstructive sleep apnea syndrome. The primary end point was defined as a composite of hypoxemia, hypotensive, or hypertensive events requiring intervention or leading to procedure discontinuation. Secondary end points included hemodynamic instability events, procedure time, serious adverse events, and patient satisfaction. RESULTS: One-hundred twenty-seven patients (mean age 62.9±10.3 years, 35.1% women, 47.2% with paroxysmal atrial fibrillation) were enrolled and randomized to the P (n=42), R (n=43), or TIVA (n=42) arms. The primary end point occurred in 85.7% of P patients, 27.9% of R patients, and 66.7% of TIVA patients (P<0.001), driven by hypoxemia in the P arm (100% of patients with the primary end point) and by hypotension in the TIVA arm (100%). The R arm showed a similar distribution of hypoxemia (50%) and hypotensive (66.7%) events. No differences were observed in mean procedural time, rate of serious adverse events, and assessment of patient satisfaction. CONCLUSIONS: In pulsed-field ablation procedures for atrial fibrillation, remimazolam-ketamine DAS was superior to propofol-opioid regimens (either boluses or continuous) and had the lowest risk of hypoxemia and hypotensive events. More than 80% of patients undergoing conventional propofol-opioid analgosedation experienced hypoxemia. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06013345.
引用
- Sochorová V, Kunštátová V, Osmančík P, et al. COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial. Circulation. 2025. PMID: 40287932. doi:10.1161/CIRCULATIONAHA.125.074427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。